Short answer
Benitec Biopharma Inc. (BNTC) filed an 8-K current report with the SEC on October 5, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Benitec received formal FDA feedback following a Type C meeting held in Q3 2026.
Benitec Biopharma Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Benitec received formal FDA feedback following a Type C meeting held in Q3 2026
- October 5, 2026 press release provides the company’s regulatory update
- FDA feedback may shape Benitec’s clinical development and regulatory strategy
Item EX-99.1 · Exhibit EX-99.1
- FDA requested additional OPMD Natural History Study data before confirming BB-301 pivotal design, creating modest regulatory execution risk
- Final pivotal study design targeted for 1Q 2027, with patient enrollment still planned for mid-2027
- Upcoming ESGCT presentation includes 12-month data for six Cohort 1 patients and interim data for three Cohort 2 patients
- BB-301 targets a rare disease affecting nearly 15,000 patients, with no approved OPMD therapies currently available
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Benitec Biopharma Inc. 8-K filings
Get the next BNTC 8-K as it lands
Follow BNTC for push alerts, or ask the research agent what this filing means.